Zhang et al [17] found that circulating B7-H3 was a valuable biomarker for nonsmall cell lung cancer (NSCLC), and an elevated level of circulating B7-H3 suggested a poor clinical outcome for NSCLC. This evidence concerns the gene CD276 and lung cancer.